IP Library Granted Patent US 9,758,769
Granted Patent B2
US 9,758,769 · App. 15/154,636 · Granted Sep 12, 2017

Car enzymes and improved production of fatty alcohols

Inventors: Derek L. Greenfield (South San Francisco, CA); Elizabeth Clarke (South San Francisco, CA); Eli Groban (South San Francisco, CA); Vikranth Arlagadda (South San Francisco, CA); Sungwon Lee (South San Francisco, CA); Xuezhi Li (South San Francisco, CA); Zhihao Hu (South San Francisco, CA); Baolong Zhu (South San Francisco, CA)
Assignee: REG LIFE SCIENCES, LLC
C12N9/0008C12P7/04C12Y102/99006C12P7/6409Y02P20/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,758,769
App. No.
15/154,636
Granted
Sep 12, 2017
Kind
B2
Abstract

The disclosure relates to variant carboxylic acid reductase (CAR) enzymes for the improved production of fatty alcohols in recombinant host cells.

Claims (74)

1. A variant carboxylic acid reductase (CAR) polypeptide comprising an amino acid sequence having at least about 85% sequence identity to SEQ ID NO: 7, wherein the variant CAR polypeptide is genetically engineered to have at least one mutation at an amino acid position selected from the group consisting of amino acid positions 3, 18, 20, 22, 80, 87, 191, 288, 473, 535, 750, 827, 870, 873, 926, 927, 930, and 1128.

2. The variant CAR polypeptide of claim 1 , wherein expression of the variant CAR polypeptide in a recombinant host cell results in a higher titer of fatty alcohol compositions compared to a recombinant host cell expressing a corresponding wild type polypeptide.

3. The variant CAR polypeptide of claim 1 , wherein the CAR polypeptide is a CarB polypeptide.

4. The variant CAR polypeptide of claim 1 , wherein the variant CAR polypeptide comprises a mutation selected from the group consisting of S3R, D18R, D18L, D18T, D18P, E20V, E20S, E20R, S22R, S22N, S22G, L80R, R87G, R87E, V191S, F288R, F288S, F288G, Q473L, Q473W, Q473Y, Q473I, Q473H, A535S, D750A, R827C, R827A, 1870L, R873S, V926A, V926E, S927K, S927G, M930K, M930R and L1128W.

5. The variant CAR polypeptide of claim 4 , wherein the variant CAR polypeptide comprises mutation A535S.

6. The variant CAR polypeptide of claim 4 , wherein the variant polypeptide comprises a combination of mutations selected from the group consisting of:

E20R, F288G, Q473I, A535S;

E20R, F288G, Q473H, A535S, R827A, S927G;

E20R, S22R, F288G, Q473H, A535S, R827A, S927G;

S3R, E20R, S22R, F288G, Q473H, A535S, R873S, S927G, M930R, L1128W;

E20R, S22R, F288G, Q473H, A535S, R873S, S927G, M930R, L1128W;

D18R, E20R, S22R, F288G, Q473I, A535S, S927G, M930K, L1128W;

E20R, S22R, F288G, Q473I, A535S, R827C, V926E, S927K, M930R;

D18R, E20R, 288G, Q473I, A535S, R827C, V926E, M930K, L1128W;

E20R, S22R, F288G, Q473H, A535S, R827C, V926A, S927K, M930R;

E20R, S22R, F288G, Q473H, A535S, R827C;

E20R, S22R, F288G, Q473I, A535S, R827C, M930R;

E20R, S22R, F288G, Q473I, A535S, I870L, S927G, M930R;

E20R, S22R, F288G, Q473I, A535S, I870L, S927G;

D18R, E20R, S22R, F288G, Q473I, A535S, R827C, I870L, V926A, S927G;

E20R, S22R, F288G, Q473H, A535S, R827C, I870L, L1128W;

D18R, E20R, S22R, F288G, Q473H, A535S, R827C, I870L, S927G, L1128W;

E20R, S22R, F288G, Q473I, A535S, R827C, I870L, S927G, L1128W;

E20R, S22R, F288G, Q473I, A535S, R827C, I870L, S927G, M930K, L1128W;

E20R, S22R, F288G, Q473H, A535S, I870L, S927G, M930K;

E20R, F288G, Q473I, A535S, I870L, M930K;

E20R, S22R, F288G, Q473H, A535S, S927G, M930K, L1128W;

D18R, E20R, S22R, F288G, Q473I, A535S, S927G, L1128W;

E20R, S22R, F288G, Q473I, A535S, R827C, I870L, S927G;

D18R, E20R, S22R, F288G, Q473I, A535S, R827C, I870L, S927G, L1128W;

D18R, E20R, S22R, F288G, Q473I, A535S, S927G, M930R, L1128W;

E20R, S22R, F288G, Q473H, A535S, V926E, S927G, M930R; and

E20R, S22R, F288G, Q473H, A535S, R827C, I870L, V926A, L1128W.

7. A recombinant host cell comprising an exogenous polynucleotide sequence encoding a variant carboxylic acid reductase (CAR) polypeptide having at least 85% sequence identity to SEQ ID NO: 7 and having at least one mutation at an amino acid position selected from the group consisting of position 3, 18, 20, 22, 80, 87, 191, 288, 473, 535, 750, 827, 870, 873, 926, 927, 930, and 1128, wherein the recombinant host cell produces a fatty alcohol composition at a higher titer or yield than a host cell expressing a corresponding wild type CAR polypeptide when cultured in a medium containing a carbon source under conditions effective to express the variant CAR polypeptide.

8. The recombinant host cell of claim 7 , wherein the SEQ ID NO: 7 is the corresponding wild type CAR polypeptide.

9. The recombinant host cell of claim 7 , further comprising a polynucleotide encoding a) a thioesterase polypeptide; b) a FabB polypeptide and a FadR polypeptide; or c) fatty aldehyde reductase (AlrA) polypeptide.

10. The recombinant host cell of claim 7 , wherein the host cell is selected from the group consisting of a plant cell, an insect cell, a fungal cell, an algal cell, and a bacterial cell.

11. The recombinant host cell of claim 10 , wherein the host cell is a bacterial cell.

12. The recombinant host cell of claim 11 , wherein the bacterial cell is an E. coli cell.

13. A method of making a fatty alcohol composition comprising culturing a recombinant host cell comprising an exogenous polynucleotide sequence encoding a variant carboxylic acid reductase (CAR) polypeptide having at least 85% sequence identity to SEQ ID NO: 7 and having at least one mutation at an amino acid position selected from the group consisting of amino acid positions 3, 18, 20, 22, 80, 87, 191, 288, 473, 535, 750, 827, 870, 873, 926, 927, 930, and 1128, in a culture medium comprising a carbon source under conditions suitable to produce the fatty alcohol composition, wherein the fatty alcohol composition is released from the host cell into the culture medium.

14. The method of claim 13 , wherein the variant CAR polypeptide comprises a mutation selected from the group consisting of S3R, D18R, D18L, D18T, D18P, E20V, E20S, E20R, S22R, S22N, S22G, L80R, R87G, R87E, V191S, F288R, F288S, F288G, Q473L, Q473W, Q473Y, Q473I, Q473H, A535S, D750A, R827C, R827A, I870L, R873S, V926A, V926E, S927K, S927G, M930K, M930R, and L1128W.

15. The method of claim 14 , wherein the variant CAR polypeptide comprises mutation A535S.

16. The method of claim 14 , wherein the variant CAR polypeptide comprises a combination of mutations selected from the group consisting of:

E20R, F288G, Q473I, A535S;

E20R, F288G, Q473H, A535S, R827A, S927G;

E20R, S22R, F288G, Q473H, A535S, R827A, S927G;

S3R, E20R, S22R, F288G, Q473H, A535S, R873S, S927G, M930R, L1128W;

E20R, S22R, F288G, Q473H, A535S, R873S, S927G, M930R, L1128W;

D18R, E20R, S22R, F288G, Q473I, A535S, S927G, M930K, L1128W;

E20R, S22R, F288G, Q473I, A535S, R827C, V926E, S927K, M930R;

D18R, E20R, 288G, Q473I, A535S, R827C, V926E, M930K, L1128W;

E20R, S22R, F288G, Q473H, A535S, R827C, V926A, S927K, M930R;

E20R, S22R, F288G, Q473H, A535S, R827C;

E20R, S22R, F288G, Q473I, A535S, R827C, M930R;

E20R, S22R, F288G, Q473I, A535S, I870L, S927G, M930R;

E20R, S22R, F288G, Q473I, A535S, I870L, S927G;

D18R, E20R, S22R, F288G, Q473I, A535S, R827C, I870L, V926A, S927G;

E20R, S22R, F288G, Q473H, A535S, R827C, I870L, L1128W;

D18R, E20R, S22R, F288G, Q473H, A535S, R827C, I870L, S927G, L1128W;

E20R, S22R, F288G, Q473I, A535S, R827C, I870L, S927G, L1128W;

E20R, S22R, F288G, Q473I, A535S, R827C, I870L, S927G, M930K, L1128W;

E20R, S22R, F288G, Q473H, A535S, I870L, S927G, M930K;

E20R, F288G, Q473I, A535S, I870L, M930K;

E20R, S22R, F288G, Q473H, A535S, S927G, M930K, L1128W;

D18R, E20R, S22R, F288G, Q473I, A535S, S927G, L1128W;

E20R, S22R, F288G, Q473I, A535S, R827C, I870L, S927G;

D18R, E20R, S22R, F288G, Q473I, A535S, R827C, I870L, S927G, L1128W;

D18R, E20R, S22R, F288G, Q473I, A535S, S927G, M930R, L1128W;

E20R, S22R, F288G, Q473H, A535S, V926E, S927G, M930R; and

E20R, S22R, F288G, Q473H, A535S, R827C, I870L, V926A, L1128W.

17. The method of claim 13 , wherein the host cell further comprises a polynucleotide encoding a) a thioesterase polypeptide; b) a FabB polypeptide and a FadR polypeptide; or c) fatty aldehyde reductase (AlrA) polypeptide.

18. The method of claim 13 , wherein the host cell is selected from the group consisting of a plant cell, an insect cell, a fungal cell, an algal cell, and a bacterial cell.

19. The method of claim 18 , wherein the host cell is a bacterial cell.

20. The method of claim 19 , wherein the bacterial cell is an E. coli cell.

Assignments (5)
SECURITY INTEREST Recorded Feb 10, 2026
From: GENOMATICA, INC.
To: AGAIN BIO APS
Reel/Frame 074708/0001 →
SECURITY INTEREST Recorded Dec 9, 2025
From: GENOMATICA, INC.
To: NOVO HOLDINGS A/S, AS COLLATERAL AGENT
Reel/Frame 073915/0027 →
SECURITY INTEREST Recorded Jun 2, 2025
From: GENOMATICA, INC.
To: OXFORD FINANCE LLC
Reel/Frame 071471/0770 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2019
From: REG LIFE SCIENCES, LLC
To: GENOMATICA, INC.
Reel/Frame 050695/0661 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2019
From: GREENFIELD, DEREK L.; CLARKE, ELIZABETH J.; GROBAN, ELI S.; ARLAGADDA, VIKRANTH; LEE, SUNGWON; LI, XUEZHI; HU, ZHIHAO; ZHU, BAOLONG
To: REG LIFE SCIENCES, LLC
Reel/Frame 048791/0212 →
Continuity (3)
Continuation 14390350
Provisional Application 61619309 · Apr 2, 2012
Related Publication 20160326499A1 · Nov 10, 2016